The Latin America, Middle East and Africa Protein Therapeutics Market is expected to witness market growth of 10.2% CAGR during the forecast period (2022-2028).
Protein treatments can offer effective replacement therapy without the requirement for gene therapy that is not currently available for the majority of genetic illnesses, for diseases in which, a gene is mutated or deleted. Besides, protein therapies may develop clinically and receive FDA approval more quickly than small-molecule medications. Additionally, because proteins are distinctive in both structure and function, businesses can acquire extensive patent protection for protein treatments.
Nowadays, genetic engineering and recombinant DNA technology have been developed, due to which, a large range of human proteins can be produced. The market for therapeutic proteins has expanded to new levels as a result of this cutting-edge technology. Recombinant DNA technology has facilitated the production of protein therapies and is taking the place of conventional natural extraction techniques.
Moreover, because many of the therapeutic proteins are produced by the body naturally, these drugs are frequently well tolerated and less likely to trigger immunological reactions. Research and development of mammalian cell-based manufacturing methods are being driven by the increased demand for high-quality recombinant medicines in an effort to increase production yields.
The prevalence of metabolic disorders is very high in Africa. The constellation of risk factors for cardiovascular disease is known as metabolic syndrome. Contrary to what was once believed, metabolic syndrome is now common throughout Africa. The prevalence is rising and tends to do so as people get older. The shift from conventional African to western lifestyles is assumed to be the cause of the country's rising prevalence of metabolic syndrome. It is not just a problem for adults in Africa, but young people are also starting to experience it more frequently.
The Brazil market dominated the LAMEA Protein Therapeutics Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $7,974.1 million by 2028. The Argentina market is expected to exhibit a CAGR of 10.8% during (2022 - 2028). Additionally, The UAE market is expected to witness a CAGR of 9.9% during (2022 - 2028).
Based on Product, the market is segmented into Monoclonal Antibodies, Human Growth Hormone, Fusion Protein, Insulin, Erythropoietin, Interferon and Follicle Stimulating Hormone. Based on Application, the market is segmented into Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Baxter International, Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Merck & Co., Inc., Johnson & Johnson (Janssen Global Services, LLC), Pfizer, Inc., Novo Nordisk A/S and Sanofi S.A.
Protein treatments can offer effective replacement therapy without the requirement for gene therapy that is not currently available for the majority of genetic illnesses, for diseases in which, a gene is mutated or deleted. Besides, protein therapies may develop clinically and receive FDA approval more quickly than small-molecule medications. Additionally, because proteins are distinctive in both structure and function, businesses can acquire extensive patent protection for protein treatments.
Nowadays, genetic engineering and recombinant DNA technology have been developed, due to which, a large range of human proteins can be produced. The market for therapeutic proteins has expanded to new levels as a result of this cutting-edge technology. Recombinant DNA technology has facilitated the production of protein therapies and is taking the place of conventional natural extraction techniques.
Moreover, because many of the therapeutic proteins are produced by the body naturally, these drugs are frequently well tolerated and less likely to trigger immunological reactions. Research and development of mammalian cell-based manufacturing methods are being driven by the increased demand for high-quality recombinant medicines in an effort to increase production yields.
The prevalence of metabolic disorders is very high in Africa. The constellation of risk factors for cardiovascular disease is known as metabolic syndrome. Contrary to what was once believed, metabolic syndrome is now common throughout Africa. The prevalence is rising and tends to do so as people get older. The shift from conventional African to western lifestyles is assumed to be the cause of the country's rising prevalence of metabolic syndrome. It is not just a problem for adults in Africa, but young people are also starting to experience it more frequently.
The Brazil market dominated the LAMEA Protein Therapeutics Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $7,974.1 million by 2028. The Argentina market is expected to exhibit a CAGR of 10.8% during (2022 - 2028). Additionally, The UAE market is expected to witness a CAGR of 9.9% during (2022 - 2028).
Based on Product, the market is segmented into Monoclonal Antibodies, Human Growth Hormone, Fusion Protein, Insulin, Erythropoietin, Interferon and Follicle Stimulating Hormone. Based on Application, the market is segmented into Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Baxter International, Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Merck & Co., Inc., Johnson & Johnson (Janssen Global Services, LLC), Pfizer, Inc., Novo Nordisk A/S and Sanofi S.A.
Scope of the Study
Market Segments Covered in the Report:
By Product- Monoclonal Antibodies
- Human Growth Hormone
- Fusion Protein
- Insulin
- Erythropoietin
- Interferon
- Follicle Stimulating Hormone
- Metabolic Disorders
- Immunologic Disorders
- Hematological Disorders
- Cancer
- Hormonal Disorders
- Genetic Disorders
- Others
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Baxter International, Inc.
- Amgen, Inc.
- F. Hoffmann-La Roche Ltd.
- Eli Lilly And Company
- Merck & Co., Inc.
- Johnson & Johnson (Janssen Global Services, LLC)
- Pfizer, Inc.
- Novo Nordisk A/S
- Sanofi S.A.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. LAMEA Protein Therapeutics Market by Product
Chapter 5. LAMEA Protein Therapeutics Market by Application
Chapter 6. LAMEA Protein Therapeutics Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Baxter International, Inc.
- Amgen, Inc.
- F. Hoffmann-La Roche Ltd.
- Eli Lilly And Company
- Merck & Co., Inc.
- Johnson & Johnson (Janssen Global Services, LLC)
- Pfizer, Inc.
- Novo Nordisk A/S
- Sanofi S.A.
Methodology
LOADING...
